SION News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SI

Mkt Cap

$176.5M

Volume

1.29M

Next Earnings

November 4th

Loading chart

SI

SIONSionna Therapeutics, Inc. Common Stock

SION

Pay with—

Available Balance0.00

SI

Mkt Cap

$184.5M

Volume

1.29M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONPomerantz LLP is investigating potential securities fraud claims against Sionna Therapeutics following the company's August 10, 2026 announcement that its PreciSION CF Phase 2a trial failed to achieve its key activity endpoint. The failure to demonstrate efficacy of SION-719 when combined with Trikafta resulted in a dramatic 91.18% stock price decline, falling from approximately $51.04 to $4.50 per share.GlobeNewswire Inc. · Oct 6, 2026

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock DownSionna Therapeutics announced a 46% workforce reduction and major restructuring following the failure of SION-719 to meet its primary endpoint in a cystic fibrosis study. The company is shifting focus to its dual combination therapy SION-451 + SION-2222, which it plans to advance into phase IIa trials in 2027. The restructuring is expected to extend cash runway into the second half of 2029.Zacks Investment Research · Sep 16, 2026

SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the FirmLaw firm Bragar Eagel & Squire is investigating Sionna Therapeutics after the company announced its SION-719 Phase 2a trial failed to achieve its primary endpoint for sweat chloride reduction. The stock price fell over 91% following the announcement. The firm is encouraging affected shareholders to contact them regarding potential securities law violations.GlobeNewswire Inc. · Sep 2, 2026

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmGlancy Prongay Wolke & Rotter LLP is investigating Sionna Therapeutics for potential securities law violations following the company's announcement of a primary endpoint miss in its PreciSION CF Phase 2a trial on August 10, 2026. The news triggered a 91.2% stock price decline, falling from approximately $46.64 to $4.10 per share, prompting a class action lawsuit on behalf of affected shareholders.GlobeNewswire Inc. · Aug 26, 2026

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzThe Law Offices of Frank R. Cruz is investigating Sionna Therapeutics for potential federal securities law violations following the company's announcement of a primary endpoint miss in its PreciSION CF Phase 2a trial on August 10, 2026. The news triggered a 91.2% stock price decline, falling from approximately $46.64 to $4.10 per share, causing significant investor losses.GlobeNewswire Inc. · Aug 25, 2026

Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationLaw Offices of Howard G. Smith is investigating potential securities fraud violations at Sionna Therapeutics, Lincoln Educational Services, and Flotek Industries on behalf of shareholders who suffered losses. Sionna's stock plummeted 91.2% following disappointing Phase 2a trial results and a decision not to advance its lead candidate.GlobeNewswire Inc. · Aug 25, 2026

Lincoln Educational Services Corp. (LINC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationLaw Offices of Howard G. Smith is investigating potential federal securities law violations at Lincoln Educational Services Corp., Sionna Therapeutics, Inc., and Flotek Industries, Inc. on behalf of shareholders who suffered losses. Lincoln Educational's stock fell 24.93% following disappointing Q2 2026 earnings that revealed only 1% student start growth and system-wide issues.GlobeNewswire Inc. · Aug 25, 2026

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still AheadVertex Pharmaceuticals strengthens its dominant position in the cystic fibrosis market after competitor Sionna Therapeutics failed a clinical trial for its CF drug candidate. With continued CF portfolio improvements, patent exclusivity until the late 2030s, and promising newer medicines like Casgevy for rare blood diseases and Journavx for pain management, Wall Street remains bullish on Vertex's growth prospects.The Motley Fool · Aug 20, 2026

Sionna Therapeutics to Participate in Upcoming June 2026 Investor ConferencesSionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment, announced its participation in two major investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10th. The company is developing novel medicines targeting the CFTR protein, with a pipeline of small molecules designed to correct defects caused by the F508del genetic mutation.GlobeNewswire Inc. · May 27, 2026

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceSionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment, announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 20th, 2026. The company is developing novel medicines targeting the CFTR protein, with a focus on NBD1 stabilizers to address the F508del genetic mutation.GlobeNewswire Inc. · May 13, 2026

to start trading

SI

SIONSionna Therapeutics, Inc. Common Stock

SION

Pay with—

Available Balance0.00

Your PositionYou don't own any SION yet.

Related Tickers

Earnings